United States · Platforms & data · The Motley Fool

JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?

Published by The Motley Fool · United States 40 min ago

JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now? — JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now? · The Motley Fool

Detailed summary

Novo Nordisk lived up to expectations for its Wegovy pill in the third quarter, but it still has more work ahead.

Read the full article on The Motley Fool Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

Apollo Global Management Sees Private Credit Demand Holding Up Despite Negative Headlines

Nvidia’s stock drops as the board reportedly prepares to remove CEO Jensen Huang

Miami International Holdings EVP sells $819,188 in stock

AEVEX shares jump as drone maker tops revenue estimates, raises outlook

Prediction markets tied to clinical trials and drug approvals draw lawmakers' ire

Can PYPL Stock Build On Its Recovery? This Analyst Raises Target To $60, Burry Is Also Adding Shares